and yet we have someone "normal" appointed to head FDA You can argue that this is because they have to pass senate confirmation, but I don't think the incoming FDA head is on board w just anyone at CBER or CDER. Let's see what happens now that Makary is about to be sworn in. Here is a Forbes piece arguing his agenda may be to accelerate drug approvals:
The vaccine story remains troubling of course, but if you can point me to a very depressed pure play vaccine company I would consider investing (MNTA BNTX have too much other baggage). I don't think significantly fewer folks are truly going to stop getting their vaccinations, but new approvals could be more challenging in certain select areas (e.g. mrna flu where older platforms w decades of safety exist)
as related to enanta i doubt cdc/acip is going to expand RSV vaccinations in older adults regardless of any updated safety data, which means the adult antiviral market if anything is going to benefit from this vaccine nonsense
Market Data 
Markets 
AI
